AP2460A - Pyrimidinyl-piperazines useful as dopamine D3/D2 receptor ligands - Google Patents

Pyrimidinyl-piperazines useful as dopamine D3/D2 receptor ligands

Info

Publication number
AP2460A
AP2460A AP2009004970A AP2009004970A AP2460A AP 2460 A AP2460 A AP 2460A AP 2009004970 A AP2009004970 A AP 2009004970A AP 2009004970 A AP2009004970 A AP 2009004970A AP 2460 A AP2460 A AP 2460A
Authority
AP
ARIPO
Prior art keywords
dopamine
pyrimidinyl
receptor ligands
piperazines useful
piperazines
Prior art date
Application number
AP2009004970A
Other languages
English (en)
Other versions
AP2009004970A0 (en
Inventor
Szalai Gizella Bartane
Csongor Eva Againe
Gyorgy Domany
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of AP2009004970A0 publication Critical patent/AP2009004970A0/xx
Application granted granted Critical
Publication of AP2460A publication Critical patent/AP2460A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2009004970A 2007-04-11 2008-04-10 Pyrimidinyl-piperazines useful as dopamine D3/D2 receptor ligands AP2460A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0700269A HUP0700269A2 (en) 2007-04-11 2007-04-11 Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use

Publications (2)

Publication Number Publication Date
AP2009004970A0 AP2009004970A0 (en) 2009-10-31
AP2460A true AP2460A (en) 2012-09-13

Family

ID=38336883

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009004970A AP2460A (en) 2007-04-11 2008-04-10 Pyrimidinyl-piperazines useful as dopamine D3/D2 receptor ligands

Country Status (36)

Country Link
EP (1) EP2132185B1 (ko)
JP (1) JP4580464B2 (ko)
KR (1) KR101540821B1 (ko)
CN (1) CN101652351B (ko)
AP (1) AP2460A (ko)
AT (1) ATE518843T1 (ko)
AU (1) AU2008237696B2 (ko)
BR (1) BRPI0809641A2 (ko)
CA (1) CA2682817C (ko)
CO (1) CO6241116A2 (ko)
CR (1) CR11071A (ko)
CU (1) CU23853B1 (ko)
CY (1) CY1111962T1 (ko)
DK (1) DK2132185T3 (ko)
EA (1) EA016174B1 (ko)
EC (1) ECSP099702A (ko)
ES (1) ES2370748T3 (ko)
GE (1) GEP20115272B (ko)
HK (1) HK1134491A1 (ko)
HR (1) HRP20110785T8 (ko)
HU (1) HUP0700269A2 (ko)
IL (1) IL200801A0 (ko)
MA (1) MA31359B1 (ko)
MX (1) MX2009010896A (ko)
MY (1) MY148384A (ko)
NI (1) NI200900179A (ko)
NZ (1) NZ579754A (ko)
PL (1) PL2132185T3 (ko)
PT (1) PT2132185E (ko)
RS (1) RS51979B (ko)
SI (1) SI2132185T1 (ko)
TN (1) TN2009000386A1 (ko)
TW (1) TWI445534B (ko)
UA (1) UA103748C2 (ko)
WO (1) WO2008125891A2 (ko)
ZA (1) ZA200906543B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9091489B2 (en) 2010-05-14 2015-07-28 Paragon Space Development Corporation Radiator systems
NZ605431A (en) 2010-06-18 2015-06-26 Altos Therapeutics Llc D2 antagonists, methods of synthesis and methods of use
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
HU229987B1 (en) * 2012-11-21 2015-04-28 Richter Gedeon Nyrt Process for the preparation of pyrimidinyl-piperazines
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
JPWO2019146739A1 (ja) 2018-01-26 2021-01-07 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する縮環化合物
WO2019146740A1 (ja) * 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051244A (en) * 1975-05-23 1977-09-27 Mar-Pha Societe D'etudes Et D'exploitation De Marques 2,4-diamino 5-bromo 6-chloro pyrimidines, process for their preparation and use as pharmaceuticals
EP0431580A2 (en) * 1989-12-06 1991-06-12 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
WO2005012266A1 (en) * 2003-08-04 2005-02-10 Richter Gedeon Vegyészeti Gyár Rt. (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957921A (en) 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051244A (en) * 1975-05-23 1977-09-27 Mar-Pha Societe D'etudes Et D'exploitation De Marques 2,4-diamino 5-bromo 6-chloro pyrimidines, process for their preparation and use as pharmaceuticals
EP0431580A2 (en) * 1989-12-06 1991-06-12 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
WO2005012266A1 (en) * 2003-08-04 2005-02-10 Richter Gedeon Vegyészeti Gyár Rt. (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists

Also Published As

Publication number Publication date
BRPI0809641A2 (pt) 2014-11-11
TN2009000386A1 (en) 2010-12-31
AU2008237696B2 (en) 2013-03-14
CN101652351A (zh) 2010-02-17
EP2132185B1 (en) 2011-08-03
CO6241116A2 (es) 2011-01-20
PT2132185E (pt) 2011-11-21
HUP0700269A2 (en) 2009-04-28
NI200900179A (es) 2010-06-30
GEP20115272B (en) 2011-08-25
CN101652351B (zh) 2012-07-04
PL2132185T3 (pl) 2011-12-30
CY1111962T1 (el) 2015-11-04
MY148384A (en) 2013-04-15
EP2132185A2 (en) 2009-12-16
MX2009010896A (es) 2009-12-14
TWI445534B (zh) 2014-07-21
ES2370748T3 (es) 2011-12-22
NZ579754A (en) 2011-11-25
IL200801A0 (en) 2010-05-17
DK2132185T3 (da) 2011-10-03
HRP20110785T8 (en) 2012-04-30
ECSP099702A (es) 2009-11-30
ATE518843T1 (de) 2011-08-15
KR101540821B1 (ko) 2015-07-30
CA2682817A1 (en) 2008-10-23
CU23853B1 (es) 2012-10-15
ZA200906543B (en) 2010-06-30
KR20100082713A (ko) 2010-07-19
EA016174B1 (ru) 2012-02-28
AP2009004970A0 (en) 2009-10-31
HRP20110785T1 (hr) 2011-11-30
JP2010523642A (ja) 2010-07-15
MA31359B1 (fr) 2010-05-03
CA2682817C (en) 2015-11-24
WO2008125891A2 (en) 2008-10-23
HK1134491A1 (en) 2010-04-30
WO2008125891A3 (en) 2009-01-08
TW201002328A (en) 2010-01-16
RS51979B (en) 2012-02-29
CR11071A (es) 2009-11-20
EA200901391A1 (ru) 2010-02-26
SI2132185T1 (sl) 2011-11-30
HU0700269D0 (en) 2007-05-29
AU2008237696A1 (en) 2008-10-23
UA103748C2 (uk) 2013-11-25
JP4580464B2 (ja) 2010-11-10
CU20090161A7 (es) 2011-09-21

Similar Documents

Publication Publication Date Title
GB0704407D0 (en) Compounds
GB0704394D0 (en) Compounds
ZA200905738B (en) Iron-hydrocarbon complex compounds
GB0705672D0 (en) Compounds
HK1134491A1 (en) Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands
GB0706173D0 (en) Compounds
GB0706188D0 (en) Compounds
GB0706165D0 (en) Compounds
GB0706168D0 (en) Compounds
GB0706187D0 (en) Compounds
GB0706167D0 (en) Compounds
GB0706174D0 (en) Compounds
GB0706170D0 (en) Compounds
GB0706164D0 (en) Compounds
GB0704939D0 (en) Compounds
GB0703756D0 (en) Compounds
GB0701985D0 (en) Compounds
GB0724430D0 (en) Receptor ligands
GB0706636D0 (en) Receptor ligands
GB0714245D0 (en) novel estrogwen receptor ligands
GB0702891D0 (en) Compounds
GB0700287D0 (en) Compounds
GB0706023D0 (en) Compounds
GB0702961D0 (en) Compounds
GB0706160D0 (en) Compounds